Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLXNASDAQ:ETNBNASDAQ:RARENASDAQ:RNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$63.12+3.6%$64.84$47.88▼$107.37$3.47B0.33556,076 shs327,103 shsETNB89bio$6.55+4.5%$7.95$4.16▼$11.84$956.20M1.251.31 million shs1.13 million shsRAREUltragenyx Pharmaceutical$35.91+1.4%$38.25$29.59▼$60.37$3.37B0.61812,342 shs1.54 million shsRNAAvidity Biosciences$29.45+3.3%$29.44$21.51▼$56.00$3.54B1.011.41 million shs1.76 million shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx-1.76%+1.04%-12.12%-8.47%+17.97%ETNB89bio+3.47%+5.91%-26.41%-4.71%-30.95%RAREUltragenyx Pharmaceutical-0.81%+1.37%-9.65%-14.24%-16.45%RNAAvidity Biosciences+6.98%+5.98%-7.52%-7.52%+25.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx1.9043 of 5 stars3.61.00.00.02.62.50.0ETNB89bio2.9095 of 5 stars4.41.00.00.03.31.70.6RAREUltragenyx Pharmaceutical4.4451 of 5 stars4.53.00.03.82.52.50.6RNAAvidity Biosciences2.1685 of 5 stars4.50.00.00.03.40.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.14Buy$110.6775.33% UpsideETNB89bio 2.89Moderate Buy$27.25316.03% UpsideRAREUltragenyx Pharmaceutical 2.93Moderate Buy$92.79158.38% UpsideRNAAvidity Biosciences 3.00Buy$66.69126.46% UpsideCurrent Analyst Ratings BreakdownLatest ETNB, RNA, ACLX, and RARE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025RNAAvidity BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.004/8/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)3/27/2025RAREUltragenyx PharmaceuticalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$104.00 ➝ $117.003/22/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)3/17/2025RAREUltragenyx PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.003/17/2025RNAAvidity BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.003/17/2025RNAAvidity BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.003/17/2025RNAAvidity BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.00 ➝ $65.003/14/2025ETNB89bioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$11.003/13/2025ETNB89bioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.003/13/2025RNAAvidity BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.00(Data available from 4/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M32.13N/AN/A$9.97 per share6.33ETNB89bioN/AN/AN/AN/A$5.75 per shareN/ARAREUltragenyx Pharmaceutical$560.23M6.02N/AN/A$2.76 per share13.01RNAAvidity Biosciences$10.90M324.88N/AN/A$6.76 per share4.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$70.69M-$2.00N/AN/AN/A-25.94%-8.28%-5.21%5/8/2025 (Estimated)ETNB89bio-$142.19M-$3.43N/AN/AN/AN/A-59.58%-52.21%5/8/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$6.34N/AN/AN/A-101.60%-193.80%-38.15%5/1/2025 (Estimated)RNAAvidity Biosciences-$212.22M-$2.89N/AN/AN/A-2,772.45%-27.66%-24.56%5/8/2025 (Estimated)Latest ETNB, RNA, ACLX, and RARE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ACLXArcellx-$0.84N/AN/AN/AN/AN/A5/8/2025Q1 2025ETNB89bio-$0.50N/AN/AN/AN/AN/A5/8/2025Q1 2025RNAAvidity Biosciences-$0.88N/AN/AN/A$2.63 millionN/A5/1/2025Q1 2025RAREUltragenyx Pharmaceutical-$1.58N/AN/AN/A$145.98 millionN/A3/6/2025Q4 2024ETNB89bio-$0.60-$1.02-$0.42-$1.02N/AN/A2/27/2025Q4 2024ACLXArcellx-$0.63-$0.87-$0.24-$0.87$27.42 million$15.27 million2/27/2025Q4 2024RNAAvidity Biosciences-$0.76-$0.80-$0.04-$0.80$1.74 million$2.97 million2/13/2025Q4 2024RAREUltragenyx Pharmaceutical-$1.32-$1.39-$0.07-$1.39$163.23 million$164.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AETNB89bioN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.294.29ETNB89bio0.0911.6611.66RAREUltragenyx PharmaceuticalN/A2.372.65RNAAvidity BiosciencesN/A17.7617.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%ETNB89bioN/ARAREUltragenyx Pharmaceutical97.67%RNAAvidity BiosciencesN/AInsider OwnershipCompanyInsider OwnershipACLXArcellx6.24%ETNB89bio2.80%RAREUltragenyx Pharmaceutical5.50%RNAAvidity Biosciences3.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8054.94 million50.70 millionOptionableETNB89bio40145.98 million103.15 millionOptionableRAREUltragenyx Pharmaceutical1,31093.89 million86.99 millionOptionableRNAAvidity Biosciences190120.21 million114.92 millionOptionableETNB, RNA, ACLX, and RARE HeadlinesRecent News About These CompaniesAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 21 at 4:05 PM | prnewswire.comRenaissance Technologies LLC Acquires 69,300 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)April 21 at 3:41 AM | marketbeat.comFederated Hermes Inc. Decreases Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)April 21 at 3:25 AM | marketbeat.comJump Financial LLC Acquires Shares of 95,575 Avidity Biosciences, Inc. (NASDAQ:RNA)April 20 at 4:57 AM | marketbeat.comWalleye Capital LLC Takes $2.67 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)April 20 at 4:36 AM | marketbeat.comAlliancebernstein L.P. Cuts Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)April 16, 2025 | marketbeat.comAvidity’s del-desiran for DM1 named orphan drug in JapanApril 16, 2025 | musculardystrophynews.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Sold by JPMorgan Chase & Co.April 15, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Receives $66.69 Consensus PT from AnalystsApril 15, 2025 | americanbankingnews.comAvidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Recommendation of "Buy" by BrokeragesApril 14, 2025 | marketbeat.comExodusPoint Capital Management LP Makes New $984,000 Investment in Avidity Biosciences, Inc. (NASDAQ:RNA)April 13, 2025 | marketbeat.comGeode Capital Management LLC Boosts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)April 13, 2025 | marketbeat.comFmr LLC Trims Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)April 12, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Sets New 52-Week Low - Here's WhyApril 12, 2025 | marketbeat.comDynamic Technology Lab Private Ltd Takes $402,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA)April 12, 2025 | marketbeat.comBeyond The Numbers: 13 Analysts Discuss Avidity Biosciences StockApril 11, 2025 | nasdaq.comAvidity Biosciences (NASDAQ:RNA) Shares Gap Down - Should You Sell?April 11, 2025 | marketbeat.comAvidity Biosciences' (RNA) Buy Rating Reaffirmed at Needham & Company LLCApril 11, 2025 | marketbeat.comTrexquant Investment LP Acquires 60,685 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)April 11, 2025 | marketbeat.comAvidity Biosciences receives Japan MHLW’s orphan drug status for delpacibart etedesiran to treat myotonic dystrophy type 1April 10, 2025 | pharmabiz.comSei Investments Co. Sells 19,149 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)April 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIAMGOLD Stock Climbs as Turnaround Story Gains TractionBy Jeffrey Neal Johnson | April 11, 2025View IAMGOLD Stock Climbs as Turnaround Story Gains TractionIntel-Taiwan Semiconductor Alliance Fuels Turnaround HopesBy Jeffrey Neal Johnson | April 8, 2025View Intel-Taiwan Semiconductor Alliance Fuels Turnaround HopesTop 3 S&P 500 Winners in a Losing MarketBy Ryan Hasson | April 9, 2025View Top 3 S&P 500 Winners in a Losing Market2 Penny Stocks With $10 Potential By Thomas Hughes | April 16, 2025View 2 Penny Stocks With $10 Potential 2 Reasons to Buy Apple Stock and 1 Significant RiskBy Chris Markoch | April 2, 2025View 2 Reasons to Buy Apple Stock and 1 Significant RiskETNB, RNA, ACLX, and RARE Company DescriptionsArcellx NASDAQ:ACLX$63.12 +2.19 (+3.59%) Closing price 04:00 PM EasternExtended Trading$63.13 +0.01 (+0.02%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.89bio NASDAQ:ETNB$6.55 +0.28 (+4.47%) Closing price 04:00 PM EasternExtended Trading$6.54 0.00 (-0.08%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Ultragenyx Pharmaceutical NASDAQ:RARE$35.91 +0.51 (+1.44%) Closing price 04:00 PM EasternExtended Trading$36.34 +0.44 (+1.21%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Avidity Biosciences NASDAQ:RNA$29.45 +0.93 (+3.26%) Closing price 04:00 PM EasternExtended Trading$29.47 +0.02 (+0.07%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Investors Sell Microsoft Stock on OpenAI News—Time to Buy? Medtronic: A Dividend Aristocrat With Stability and Innovation Breaking Down Taiwan Semiconductor's Earnings and Future Upside Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal UnitedHealth Group: Pariah to Pole Position to Buy the Dip Levels Why Netflix Is the "Cleanest Story in Tech" Take-Two Interactive: A Defensive Play Set to Explode NVIDIA: New Headwinds vs. Major Upside Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
